{"id":"W2613815573","doi":"10.1093/annonc/mdx091.040","title":"Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Internal medicine; Oncology; Adverse effect; Adenocarcinoma; Neutropenia; Chemotherapy; Phases of clinical research; Surgery; Cancer; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003819464,0.002213858,0.006111993,0.0005515529,0.0004890071,0.001427414,0.001096924,0.001572957,0.003774789],"category_scores_gemma":[0.003631155,0.0008137031,0.01094674,0.0004930276,0.0007363268,0.001016165,0.0007468268,0.002864186,0.0004236502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001143539,"about_ca_system_score_gemma":0.001189673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001243293,"about_ca_topic_score_gemma":0.004117098,"domain_scores_codex":[0.9979064,0.001064406,0.0002631978,0.0003760288,0.0001516809,0.0002383042],"domain_scores_gemma":[0.9985129,0.0006020037,0.0003225373,0.0002462149,0.00008654901,0.0002297421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9570599,0.0008502704,0.004022799,0.0008743847,0.02494047,0.00008225936,0.0000690916,0.0004042649,0.002821355,0.00007465896,0.0006276398,0.008172788],"study_design_scores_gemma":[0.8363343,0.04700731,0.03245306,0.0001645297,0.07747091,0.0001907186,0.0002043996,0.00188038,0.001437317,0.0006218792,0.002125126,0.0001100543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799658,0.01406134,0.0008699258,0.0007217904,0.0008373058,0.001222443,0.001339247,0.00007681282,0.0009053655],"genre_scores_gemma":[0.9938375,0.001533215,0.0007979777,0.0006708956,0.0003106199,0.0007385209,0.001188273,0.00002481323,0.000898157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006111993,"threshold_uncertainty_score":0.02019948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06405871301770999,"score_gpt":0.4300355723682339,"score_spread":0.3659768593505239,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}